As immune checkpoint inhibitors (ICI) emerge as a paradigm-shifting treatment option for patients with advanced or metastatic cancer, there is growing demand biomarkers that can distinguish which are likely to benefit. In the case of triple-negative breast cancer (TNBC), characterized by lack therapeutic targets, pembrolizumab approval high-risk early-stage disease occurred regardless PD-L1 sta...